Published in Arthritis Res Ther on August 05, 2003
Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem Biophys Res Commun (2011) 0.98
Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS One (2012) 0.87
Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health (2015) 0.84
The functional mechanism of simvastatin in experimental osteoporosis. J Bone Miner Metab (2014) 0.79
Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int (2014) 0.79
Si-Wu-tang extract stimulates bone formation through PI3K/Akt/NF-κB signaling pathways in osteoblasts. BMC Complement Altern Med (2013) 0.79
Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Osteoporos Int (2015) 0.78
Tridax procumbens flavonoids promote osteoblast differentiation and bone formation. Biol Res (2015) 0.78
Euodia sutchuenensis Dode extract stimulates osteoblast differentiation via Wnt/β-catenin pathway activation. Exp Mol Med (2015) 0.76
The effects of 6-gingerol on proliferation, differentiation, and maturation of osteoblast-like MG-63 cells. Braz J Med Biol Res (2015) 0.76
Effects of Scytosiphon lomentaria on osteoblastic proliferation and differentiation of MC3T3-E1 cells. Nutr Res Pract (2016) 0.75
Newer anabolic therapies in osteopororsis. Indian J Endocrinol Metab (2012) 0.75
Effects of Strontium Ranelate on Spinal Interbody Fusion Surgery in an Osteoporotic Rat Model. PLoS One (2017) 0.75
Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Des Devel Ther (2015) 0.75
Effects of OsteoKing on osteoporotic rabbits. Mol Med Rep (2015) 0.75
Osteoblasts Proliferation and Differentiation Stimulating Activities of the Main Components of Epimedii folium. Pharmacogn Mag (2017) 0.75
Effects of tanshinol on markers of bone turnover in ovariectomized rats and osteoblast cultures. PLoS One (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11
Effects of human growth hormone in men over 60 years old. N Engl J Med (1990) 8.19
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am (2002) 5.95
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 5.49
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am (2001) 5.13
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) (2002) 2.74
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors (1993) 2.28
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology (1999) 1.89
Growth factor regulation of fracture repair. J Bone Miner Res (1999) 1.88
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med (2003) 1.81
Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol (1993) 1.81
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med (1995) 1.72
Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res (2003) 1.71
An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res (1993) 1.60
Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br (1999) 1.56
Parathyroid hormone for treatment of osteoporosis. Arch Intern Med (2002) 1.48
Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.42
The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . J Bone Miner Res (2001) 1.32
Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am (2001) 1.29
Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res (1998) 1.26
A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int (1991) 1.23
Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res (2003) 1.20
Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res (2001) 1.17
Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun (2001) 1.10
Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol (1997) 1.09
Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology (1988) 1.08
From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) (2003) 1.07
Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol (1999) 1.04
In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine (Phila Pa 1976) (1994) 1.02
Effects of TGFbeta and bFGF on the differentiation of human bone marrow stromal fibroblasts. Cell Biol Int (1999) 0.98
Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone (1995) 0.98
HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int (2003) 0.96
Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am (2001) 0.96
Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int (2002) 0.92
Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int (2003) 0.89
Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem (1996) 0.88
Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res (1995) 0.88
Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab (2001) 0.87
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int (2003) 0.87
Anabolic effects of basic fibroblast growth factor in the tibial diaphysis of ovariectomized rats. Bone (2000) 0.86
Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. J Periodontol (1998) 0.85
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int (2001) 0.84
New anabolic therapies in osteoporosis. Curr Opin Rheumatol (2002) 0.79
Strontium ranelate in osteoporosis. Curr Pharm Des (2002) 0.79
Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats. J Bone Miner Res (2001) 0.79
Lipid clearing agents in steroid-induced osteoporosis. J Formos Med Assoc (1995) 0.78
How to grow bone to treat osteoporosis and mend fractures. Curr Rheumatol Rep (2003) 0.77
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol (2010) 1.91
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum (2010) 1.73
Pregnancy outcomes after maternal exposure to rituximab. Blood (2010) 1.29
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med (2011) 1.20
Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol (2010) 1.17
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol (2007) 1.13
Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep (2004) 1.07
Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum (2011) 1.01